PO.TB03.01 · 肿瘤生物学

使治疗耐药的缺氧转移性黑色素瘤细胞重新恢复敏感性

Resensitizing therapy-resistant anoxic metastatic melanoma cells

海报缩略图:使治疗耐药的缺氧转移性黑色素瘤细胞重新恢复敏感性
编号 2231 展板 6 时间 4/20 09:00–12:00 区域 Section 32 主讲 Gustavo Untiveros
分会场 Therapies Targeting Metastasis
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Gustavo Untiveros1, Daryl Forney1, Mariella Andrews2, Tekaswini Kannan1, Luigi Strizzi3

1Midwestern Univ. - Downers Grove Campus, Downers Grove, IL,2Loyola University - Chicago, Chicago, IL,3Pathology, Midwestern Univ. - Downers Grove Campus, Downers Grove, IL

摘要 Abstract

中文摘要
引言:转移性黑色素瘤显著降低患者生存率。转移性生长可超过血管化速度,形成极度低氧或缺氧的区域。HIF-1alpha是细胞对低氧存活反应的主要转录调控因子,可促进选择出更具干细胞样、耐药性的癌细胞。BRAF抑制剂(BRAFi)常用于治疗黑色素瘤,靶向涉及pERK依赖性黑色素瘤生长的细胞信号传导。对BRAFi的耐药可导致黑色素瘤复发和不良生存。双特异性磷酸酶(DUSP),如DUSP6,可降低ERK活性;此外,已证明DUSP6在细胞对低氧的反应过程中被HIF-1alpha上调。我们假设,随着转移性黑色素瘤细胞适应缺氧的转移微环境,其HIF-1alpha水平升高,进而增加DUSP6的表达,从而降低ERK活性,导致对BRAFi的耐药。 方法:采用蛋白质印迹(WB)比较在缺氧或常氧条件下培养的A375黑色素瘤细胞裂解物中HIF-1alpha、pERK和DUSP6的表达。采用MTT细胞增殖实验和细胞凋亡实验,比较BRAFi药物Dabrafenib对处理的常氧与缺氧A375细胞的影响。收集裂解物进行WB,以评估DUSP6抑制剂BCI处理的缺氧A375细胞与未处理对照之间pERK的效应。最后,为观察BCI是否能提高药物敏感性,对同时用BCI和Dabrafenib处理的缺氧A375细胞进行MTT和细胞凋亡实验。 结果:WB结果显示,与常氧对照细胞相比,缺氧A375细胞表达更高水平的HIF-1alpha和更低水平的pERK。Dabrafenib处理降低了常氧A375细胞的增殖,但对缺氧A375细胞无效,推测原因是这些细胞中pERK靶点的表达降低。用BCI抑制DUSP6显著增加了pERK表达,当与Dabrafenib联合使用时,显著降低了缺氧A375细胞的增殖并增加了细胞死亡。 结论:我们证明,在缺氧条件下培养的黑色素瘤细胞表达更高水平的HIF-1alpha。这进而导致DUSP6表达增加。在这些缺氧细胞中,DUSP6进而降低pERK水平,而pERK是Dabrafenib所靶向的信号级联的重要组成部分。最后,我们用BCI和Dabrafenib联合治疗的结果表明,通过抑制DUSP6,有可能在耐药的缺氧转移性黑色素瘤细胞中重新表达pERK并重建药物敏感性。
查看英文原文 English abstract
Introduction: Metastatic melanoma significantly reduces patient survival. Metastatic growth can outpace vascularization creating areas of extreme hypoxia or anoxia. HIF-1alpha is a master transcriptional regulator of cellular survival response to hypoxia that can facilitate the selection of more stem cell-like, drug-resistant cancer cells. BRAF inhibitors (BRAFi), commonly used to treat melanoma, targets cell signaling involving pERK-dependent melanoma growth. Resistance to BRAFi can lead to melanoma recurrence and poor survival. Dual specificity phosphatases (DUSP), such as DUSP6 can reduce ERK activity; moreover, DUSP6 has been shown to be upregulated by HIF-1alpha during cellular responses to hypoxia. We hypothesize that HIF-1alpha levels increase in metastatic melanoma cells as these adapt to the anoxic metastatic niche, which then increases DUSP6 expression, which in turn reduces ERK activity that causes resistance to BRAFi. Methods: Western blot (WB) was used to compare the expression of HIF-1alpha, pERK, and DUSP6 in lysates from A375 melanoma cells grown in anoxia or normoxia. An MTT cell proliferation, and a cell apoptosis assay were used to compare the effect of the BRAFi, Dabrafenib between treated normoxic and anoxic A375 cells. Lysates were collected for WB to assess effects on pERK between anoxic A375 treated with the DUSP6 inhibitor, BCI, and untreated control. Finally, to see if BCI can increase drug sensitivity, MTT and cell apoptosis assays were performed on anoxic A375 treated with both BCI and Dabrafenib. Results: WB results show that anoxic A375 cells express higher levels of HIF-1alpha, and lower levels of pERK compared to normoxic control cells. Dabrafenib treatment reduced cell proliferation of normoxic but not anoxic A375 cells, presumably due to reduced expression of the pERK target in these cells. Inhibition of DUSP6 with BCI significantly increased pERK expression and when combined with Dabrafenib significantly reduced proliferation and increased cell death of the anoxic A375 cells. Conclusion: We show that melanoma cells cultured in anoxia express higher levels of HIF-1alpha. This in turn led to an increase in DUSP6 expression. In these anoxic cells, DUSP6, in turn, reduces pERK level, which is an important component of the signaling cascade targeted by Dabrafenib. Finally, our results from the combination treatment with both BCI and Dabrafenib suggest that by inhibiting DUSP6 it may be possible to re-express pERK in drug-resistant anoxic metastatic melanoma cells and reestablish drug sensitivity.
利益披露 Disclosure
G. Untiveros, None.. D. Forney, None.. M. Andrews, None.. T. Kannan, None.. L. Strizzi, None.

← 返回 AACR 2026 检索